ZYBERNO
Stock Report
Updated Aug 31, 2026

Lyell Immunopharma, Inc. (LYEL)

Healthcare • NASDAQ

$14.53

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
23.0/100
POOR BUSINESS
Lyell Immunopharma, Inc. (LYEL) scores 23/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-91.6%)
Debt-to-Equity (Solvency Risk):GOOD (0.40x)
Operating Margin (Operational Efficiency):CRITICAL (-949,981.5%)
Return on Capital (Capital Efficiency):CRITICAL (-92.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Lyell Immunopharma, Inc. (LYEL) stock report — Zyberno Score 23/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, LYEL generated -$134.42M in Owner Earnings. Capital was deployed as follows: $623.00K invested in capital expenditures. Reinvestment rate: 5.6%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:14.53
Market Cap:$339.48M

Valuation Multiples (3)

P/B Ratio:1.45x
P/S Ratio:12,573.29x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$313.09M

Price Action & Momentum (3)

Momentum Percentile:84 / 100
% of 52-Week High:32.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-70.5%
Reinvestment Rate:5.6%
Fundamental Growth Rate (g):-5.2%

Margin Analysis (3)

Operating Margin Ttm:-949,981.5%
Net Margin Ttm:-920,285.2%
Ebitda Margin:-911,351.9%

TTM Performance (2)

Operating Margin Ttm:-949,981.5%
Net Margin Ttm:-920,285.2%

Yield Metrics (2)

Earnings Yield:-$112.99
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:50.6%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:5.36x
Quick Ratio:5.36x
Cash Ratio:1.83x

Leverage Analysis (3)

Debt To Equity Ttm:0.40x
Debt-to-Equity Ratio:0.40x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:173,674,000.00
Cash And Cash Equivalents:72,985,000.00
Long Term Debt:$36.93M
Net Debt:-$26.39M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $27.00K
Linear Growth: -50.0%
📊 Click to view full LYEL Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$256.50M

Bottom Line Performance (3)

-$248.48M
Income Before Tax:$0.00
Ebitda Ttm:-246,065,000.00

Operating Expenses (5)

Operating Expenses:256,522,000.00
R And D Expense:156,499,000.00
Sga Expense:40,434,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:3,912,475.0%
Sga To Revenue Percentage:1,010,850.0%
Ebitda Margin:-911,351.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$311.15M
Current Assets:$213.54M
Ppe Net:30,507,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:77,338,000.00
Current Liabilities:39,867,000.00
Long Term Debt:$36.93M
Short Term Debt:$9.66M

Equity & Capital (3)

Equity:$233.82M
Retained Earnings:-$1.69B
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,879,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:4,532,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$133.80M-$134.42M

Investment Activities (2)

Investing Cash Flow:$17.38M
Capital Expenditures Ttm:623,000.00

Financing Activities (3)

Financing Cash Flow:$51.72M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:50,000,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:10,430,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-16.01
-$16.01
Earnings Per Share Ttm:-$10.64

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$6.42

Book Value & Capital (2)

Book Value Per Share:$10.01
Cash Per Share:3.12

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:52,438.33
Cash Conversion Cycle:-54,436.33
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$134.42M

Damodaran Growth Analysis (2)

Reinvestment Rate:5.6%
Fundamental Growth Rate (g):-5.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-28.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:LYEL
Company Name:Lyell Immunopharma, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:23.36M
Shares Outstanding Basic:23.36M
Shares Outstanding Diluted:23.36M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 01:28:50 UTC
Data Timestamp:2026-08-18T08:03:40.762831
Scroll to Top